Table 3 Estimated laboratory parameters estimated in samples of the enrolled patients compared to samples of control subjects
Laboratory parameters | Group Data | Control (n = 20) | UC (n = 51) | IBS (n = 291) | |
|---|---|---|---|---|---|
Fecal calprotectin (µg/ml) | Average (± SD) | 31.86 ± 10.8 | 146.9 ± 54.4 | 66.4 ± 47 | |
Significance vs. control | < 0.001 | 0.0015 | |||
Significance vs. UC | < 0.001 | ||||
Patients’ distribution according to the probable diagnostic FCP levels | ≤ 50 | 20 (100%) | 0 | 162 (55.7%) | |
> 50– < 150 | 0 | 30 (58.8%) | 152 (41.9%) | ||
≥ 150 | 0 | 21 (41.2%) | 28 (2.4%) | ||
Serum CRP (mg/l) | < 5 | 20 (100%) | 11 (21.6%) | 44 (15.1%) | |
≥ 5 | 0 | 40 (78.4%) | 152 (84.9%) | ||
Average (± SD) | 2.08 ± 0.4 | 11.74 ± 8.5 | 8.81 ± 3.5 | ||
Significance vs. control | < 0.001 | < 0.001 | |||
Significance vs. UC | < 0.001 | ||||
Serum ITLN1 (ng/ml) | Average (± SD) | 29.36 ± 2.95 | 15.58 ± 3.3 | 27.69 ± 8.23 | |
Significance vs. control | < 0.001 | 0.366 | |||
Significance vs. UC | < 0.001 | ||||